サマリー

The global inhalation anesthesia market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.

Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery. Some of the commonly used inhalation anesthetics include nitrous oxide, desflurane, isoflurane and sevoflurane. These anesthetics are administered using a laryngeal face airway and a tracheal tube connected to a vaporizer. They are highly effective in small doses and can induce respiratory depression, reduce the arterial blood pressure and increase cerebral blood flow when used in unmoderated quantities. In comparison to the traditionally used intravenous variants, inhalation anesthesia does not accumulate in the body and aids in preventing excessive dosage, while promoting normal functioning of the patient.

Inhalation Anesthesia Market Trends:
The increasing prevalence of chronic medical disorders requiring surgical treatments is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to ailments, such as cardiovascular, neurological, respiratory and degenerative disorders, is providing a thrust to the market growth. Hospitals and other ambulatory healthcare centers are widely using sevoflurane and other ether-based inhalation anesthetic agents with low pungency and non-irritant odor for patients with asthma or sensitive air passages. Additionally, various technological advancements, such as the development of anesthesia recycling systems for extracting anesthetic compounds from hospital vents and operating rooms, are acting as other growth-inducing factors. In line with this, anesthesia manufacturers are also producing variants with enhanced compatibility and minimal side-effects to cater to the requirements of patients sensitive to anesthetic agents. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global inhalation anesthesia market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product, application and end user.

Breakup by Product:

Desflurane
Sevoflurane
Isoflurane
Others

Breakup by Application:

Induction
Maintenance

Breakup by End User:

Hospitals
Ambulatory Surgical Centers
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd. Key Questions Answered in This Report:
How has the global inhalation anesthesia market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global inhalation anesthesia market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global inhalation anesthesia market and who are the key players?
What is the degree of competition in the industry?

ページTOPに戻る

目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Inhalation Anesthesia Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Desflurane
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Sevoflurane
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Isoflurane
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Application
7.1 Induction
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Maintenance
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ambulatory Surgical Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbvie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Baxter International Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Fresenius SE & Co. KGaA
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Halocarbon Products Corporation
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Hikma Pharmaceuticals PLC
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Lunan Pharmaceutical Group Co. Ltd
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Merck KGaA
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Piramal Enterprises Ltd.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Troikaa Pharmaceuticals Ltd
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio